Beta Bionics Chief Commercial Officer Hopman Mark sold 775 shares at $15.52 each on 2026-09-14, leaving an ownership position of 86,382 shares. The sale represented about 0.9% of his prior holding, allowing investors to distinguish the transaction from the larger position that remained afterward.
Key Highlights
- The transaction took place on 14 September 2026 under SEC transaction code S.
- Hopman Mark held 86,382 Beta Bionics shares after the sale.
- The disposal represented about 0.9% of his prior shareholding.
Beta Bionics, Inc. (NASDAQ: BBNX) shares were sold by Chief Commercial Officer Hopman Mark in a transaction covering 775 shares at $15.52 each. The disposal represented about 0.9% of his prior holding. Hopman Mark is identified as Beta Bionics’ chief commercial officer. The transaction date was 14 September 2026. The record prices each transferred share at $15.52 and identifies the transaction as involving Beta Bionics shares.
Post-Transaction Holding Stood at 86,382 Shares
Mark held 86,382 Beta Bionics shares after completing the transaction. The reported 0.9% figure is measured against his prior shareholding, while the 86,382-share figure describes his position afterward. The two figures therefore refer to different points in the transaction timeline.
FAQs
Q: How many Beta Bionics shares did Hopman Mark sell?
A: Hopman Mark sold 775 Beta Bionics shares at $15.52 per share. The transaction occurred on 14 September 2026 and was classified under SEC code S.
Q: How many BBNX shares did Hopman Mark own after the sale?
A: Hopman Mark owned 86,382 Beta Bionics shares after the transaction. The reported ownership figure reflects his position following the sale.
Q: What percentage of Hopman Mark’s prior holding did the sale represent?
A: The Beta Bionics share sale represented about 0.9% of Hopman Mark’s prior holding. His post-transaction ownership was reported at 86,382 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.